Satoreotide trizoxetan 5-20μg

Phase 2

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Drug Information

Target Indication

Gastro-Enteropancreatic Neuroendocrine Tumor

Clinical Trial

Last updated: 1/2/2026

Developer

IPSEY

Ipsen Biopharmaceuticals, Inc.

Related Pipeline

Primary Biliary Cholangitis

Acromegaly

Biliary Atresia

Advanced Prostate Cancer

Acromegaly